Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00857623 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 127
- Enrollment target
NCT00857623 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 127 participants.
The verdict
NCT00857623, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 127 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate if AZD2066 can relieve the pain arising from painful diabetic neuropathy compared to placebo.
Interventions
- DRUG Placebo
- DRUG AZD2066
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2009-02 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00857623
The ClinicalTrials.gov registry entry for NCT00857623 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00857623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00857623 about?
NCT00857623 is a clinical study titled "Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy". The purpose of this study is to investigate if AZD2066 can relieve the pain arising from painful diabetic neuropathy compared to placebo.
What is the current status of trial NCT00857623?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 127 participants. The study started on 2009-02. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00857623?
The interventions under investigation include: Placebo (DRUG), AZD2066 (DRUG).
Who is sponsoring clinical trial NCT00857623?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.